NeurOp, Inc. is a clinical-stage, Atlanta-based biopharmaceutical company developing new medicines for central nervous system disorders, including severe pain, subarachnoid hemorrhage (SAH), and catastrophic juvenile epilepsies. Its technology targets the GluN2B subunit of neuronal NMDA receptors and its potential therapeutic benefit.
Multi-year funding from the NIH supports NeurOp's research and development programs for NP10679, its drug candidate for the prevention of ischemic damage during a stroke or subarachnoid hemorrhage (SAH) and severe pain. For more information, please visit www.neuropinc.com